Lacosamide Krka

Lacosamide, the active ingredient in Lacosamide Krka, is an Anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of partial‑onset seizures, either as monotherapy or adjunctive therapy in patients with epilepsy.

GNH USA supplies Lacosamide Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic drug that acts on neuronal sodium channels to control seizure activity. - Partial‑onset seizures: reduces the frequency and severity of focal seizures. - Adjunctive therapy for epilepsy: improves overall seizure control when added to other antiepileptic medications. - Focal seizures: helps achieve better seizure freedom in patients with focal onset epilepsy.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: sensation of lightheadedness or unsteadiness. - Nausea: mild to moderate stomach upset. - Fatigue: increased tiredness or lack of energy. - Headache: mild to moderate pain in the head. - Blurred vision: temporary visual disturbances. - Diplopia: double vision in some patients.

Serious or Rare Side Effects: - Suicidal thoughts or behavior: new or worsening mood changes. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac arrhythmias: including PR‑interval prolongation. - Respiratory depression: especially when combined with other CNS depressants. - Allergic reactions: anaphylaxis or angioedema. - Hepatotoxicity: signs of liver injury such as jaundice.

Before initiating therapy with Lacosamide, consider the following precautions. - Renal impairment: dose adjustment may be required in patients with reduced kidney function. - Hepatic impairment: monitor liver enzymes and adjust dosing as needed. - Concomitant CNS depressants: increased risk of sedation and respiratory depression. - Cardiac conduction disorders: avoid in patients with known PR‑interval prolongation. - Pregnancy: safety not established; weigh benefits against potential risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with several medications; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin): may markedly reduce lacosamide plasma levels. - Other sodium‑channel blockers (e.g., lamotrigine, oxcarbazepine): increase risk of cardiac conduction abnormalities. - QT‑prolonging agents (e.g., certain antiarrhythmics): may exacerbate cardiac rhythm effects.

Moderate Interactions (Monitor Closely): - Alcohol: additive CNS depression may increase dizziness and sedation. - Hormonal contraceptives: lacosamide may reduce contraceptive efficacy; advise alternative methods. - CYP2C19 inhibitors (e.g., fluoxetine, omeprazole): may modestly increase lacosamide exposure. - Other antiepileptics (e.g., valproate): monitor for enhanced side‑effect profile. - Anticoagulants: observe for any changes in bleeding risk, though data are limited.